Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment
{{output}}
Background: CBL-514, a small-molecule injectable lipolysis agent that induces adipocyte apoptosis, demonstrated clinically meaningful reductions in abdominal subcutaneous fat by ultrasound in previous Phase 2 studies, with no obs... ...
